Contact the ACC Registration and Housing Center

  • 864-208-2670
  • M-F, 9:00 a.m. - 5:00 p.m. ET

  • Industry-Expert Theaters
    Expo Hall, #2251 and #1951

    Learn from industry leaders as they present the latest in cardiovascular practices, products, services, and technologies while you enjoy refreshments or lunch.

    Quick Links: SaturdaySundayMonday

    Saturday, April 2

    10:15 – 11:15 a.m.

    4001. The Importance of Device Therapy in Patients With Heart Failure Across the Continuum of Care
    Industry-Expert Theater 1, #2251
    Sponsored by Abbott

    Heart failure is a complex, progressive disease with an observed increase in mortality in recent years. It has become increasingly important to recognize when medications alone are not enough and referral to device interventions may be required. In this program, cardiology experts will discuss the latest device advancements, treatment guidelines and clinical data in the treatment and management of heart failure patients across the disease continuum. The latest updates on the CardioMEMS™ HF System, MitraClip™ Therapy and HeartMate 3™ LVAD Therapy will be presented along with an expert panel discussion.

    Neil Moat, MBBS (co-moderator)
    DVP of Medical Affairs and Chief Medical Officer
    Abbott Structural Heart

    Phil Adamson, MD, FACC (co-moderator)
    DVP of Medical Affairs and Chief Medical Officer
    Abbott Heart Failure

    Terrie-Ann Benjamin, MD, MHS
    Advanced Heart Failure Cardiologist
    M Health Fairview; St. Joseph's Hospital - Heart Clinic

    Rahul Sharma, MD
    Interventional Cardiologist, Stanford Health
    Associate Professor of Medicine, Director of Structural Interventions, Stanford University

    Douglas Horstmanshof, MD
    Advanced Heart Failure and Transplant Cardiology
    Director, INTEGRIS Advanced Cardiac Care
    INTEGRIS Baptist Medical Center

    4009. PCI in Heart Failure With Reduced EF (HFrEF): The Who, the How, and the Why?
    Industry-Expert Theater 2, #1951
    Sponsored by Abiomed

    The goal of this symposium is to raise awareness about the under-diagnosis of CAD as the etiology of heart failure and review the clinical evidence of percutaneous revascularization to improve heart failure symptoms and EF as well as introduce the PROTECT IV clinical trial.

    James Januzzi, MD, FACC
    Hutter Family Professor of Medicine, Harvard Medical School
    Cardiology Division, Massachusetts General Hospital
    Cardiometabolic Trials, Baim Institute
    Trustee, American College of Cardiology

    Adam DeVore, MD, MHS
    Medical Director of the Duke Heart Transplant Program and Heart Failure Research Cluster

    Mitul Patel, MD, FACC, FSCAI
    Clinical Professor of Medicine, Director of Endovascular Interventions
    CVI Interventional Cardiology, Division of Cardiovascular Medicine

    Gregg Stone, MD
    Director of Academic Affairs for the Mount Sinai Heart Health System
    Professor of Medicine (Cardiology)
    Professor of Population Health Sciences and Policy
    The Zena and Michael A. Wiener Cardiovascular Institute

    12:45 – 1:45 p.m.

    4002. Addressing Health Disparities & Impacting Atherosclerotic Cardiovascular Disease Outcomes: What Novel Population Health Collaborations Can Teach Us
    Industry-Expert Theater 1, #2251
    Sponsored by Novartis Pharmaceuticals Corporation

    Despite the availability and enduring widespread adoption of effective lipid-lowering treatments beginning almost 40 years ago, optimal lipid levels remain elusive in most patients, including those with established atherosclerotic cardiovascular disease (ASCVD), who are at highest risk for a (recurrent) event. Lack of progress is particularly evident when accounting for gender, race, and socioeconomic factors. In the United States, cardiovascular diseases, led by ASCVD, remain the leading cause of mortality despite broad efforts to increase awareness among clinicians, patients, and government entities. This program will highlight strategies that seek to improve ASCVD prevention including ongoing efforts that have the potential to address gaps in lipid management, and a call to action for novel approaches coordinated by preventive clinician advocates, health systems, and patient/professional society partnerships across the health care ecosystem.

    Abena Osei-Wusu, MD, FACC, FSCAI
    Medical Director, Atherosclerosis
    Cardiovascular, Renal & Metabolism Medical Unit
    Novartis Pharmaceuticals Corporation

    Jason LeCocq, MD, MBA
    Medical Director, Atherosclerosis
    US Clinical Development & Medical Affairs
    Cardiovascular & Metabolism
    Novartis Pharmaceuticals Corporation

    4010. Add on Efficacy: Oral, Nonstatin Therapies For Lowering LDL-C
    Industry-Expert Theater 2, #1951
    Sponsored by Esperion Therapeutics

    The session will cover the following information:

    • Atherosclerotic cardiovascular disease and lipid management
    • Unique mechanism of action for two treatment options
    • Efficacy data for two treatment options
    • Safety data for two treatment options
    • Overview of the ongoing Outcomes trial

    Matthew Budoff, MD
    Professor of Medicine, UCLA
    Endowed Chair of Preventive Cardiology
    Lundquist Institute
    Torrance, California

    3:15 – 4:15 p.m.

    4003. Help Your MI Patients Achieve Lower LDL-C and Reduce the Risk of Another MI
    Industry-Expert Theater 1, #2251
    Sponsored by Amgen

    Join Dr. Norman Lepor for an educational presentation on the treatment of very high-risk ASCVD patients described in the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Hear about his experience and the treatment options available for appropriate patients.

    Norman Lepor, MD, FACC

    4011. Jardiance® (empagliflozin) Tablets: A Review of the Latest Data
    Industry-Expert Theater 2, #1951
    Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC

    This program will review recent clinical trial data for JARDIANCE. It will also provide information on JARDIANCE initiation and dosing, as well as guidance for monitoring patients on JARDIANCE. Attendees will have the opportunity to ask the faculty questions about the data presented.

    Javed Butler, MD, MPH, MBA
    President, Baylor Scott and White Research Institute
    Senior Vice President, Baylor Scott and White Health
    Distinguished Professor of Medicine, University of Mississippi

    Sunday, April 3

    9:15 – 10:15 a.m.

    4004. Connecting the Dots: From Symptoms to Diagnosis and Treatment of ATTR-CM
    Industry-Expert Theater 1, #2251
    Sponsored by Pfizer

    Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease that frequently presents as heart failure. ATTR-CM is underrecognized, with symptoms that can span multiple organ systems, resulting in delayed diagnosis and increased disease burden. This program provides an overview of ATTR-CM pathology and highlights the signs and symptoms that raise suspicion of ATTR-CM, as well as diagnostic approaches used to confirm suspicion. The program also presents clinical data supporting an oral treatment option for patients with this life-threatening disease.

    Brett Sperry, MD
    Cardiologist, Mid America Heart Institute
    Assistant Professor of Medicine, University of Missouri-Kansas City

    Catherine Marti, MD, MSc
    Director of Cardiovascular Services, Compassionate Care Hospice Agency
    Cardiologist, Piedmont Heart Institute

    4012. LEQVIO® (inclisiran): A Bold Way Forward. How Can Innovation Transform The Way We Treat LDL-C In Patients With ASCVD?
    Industry-Expert Theater 2, #1951
    Sponsored by Novartis Pharmaceuticals Corporation

    This program will present the unmet needs for patients with ASCVD and persistently elevated LDL-C despite best efforts with statin therapy, and how LEQVIO may be able to help. We will highlight the pivotal efficacy and safety data for LEQVIO, cover how to acquire and administer the medication, and review types of patients who may be appropriate for this new therapeutic option.

    Mark Stampehl, MD, FACC
    Executive Medical Director
    Novartis Pharmaceuticals Corporation

    11:15 a.m. – 12:15 p.m.

    4005. A Focus on Very High-Risk Patients in the Acute Setting: Understanding Vulnerable Plaque and Prioritizing LDL-C
    Industry-Expert Theater 1, #2251
    Sponsored by Amgen

    In this presentation we will discuss the importance of cholesterol management in very high-risk ACSVD patients in the acute setting and focus on plaque vulnerability and the role of LDL-C. Don't miss this informative presentation and discussion of a treatment option.

    Usman Baber, MD, MS, FACC, FSCAI
    Director, Interventional Cardiology and Cardiac Catheterization Laboratory
    Associate Professor of Medicine (Cardiology), University of Oklahoma Health Sciences Center

    Payal Kohli, MD, FACC
    Founder, Cherry Creek Heart
    Assistant Clinical Professor of Medicine, University of Colorado Anschutz

    4013. Treating Recurrent Pericarditis and Preventing Recurrence
    Industry-Expert Theater 2, #1951
    Sponsored by Kiniksa Pharmaceuticals, Ltd

    For many individuals, the first acute episode of pericarditis is just the beginning of their journey. Some patients continue to experience multiple recurrences and may face both physical and mental challenges regardless of treatment. Managing recurrent pericarditis (RP) can also be a challenge for clinicians because most commonly prescribed traditional therapies for RP only address symptom relief. At this Industry-Expert Theater session, you will review the diagnosis of RP, the underlying pathophysiology that drives the repetitive cycle of recurrence, and a treatment for RP.

    Timothy D. Henry, MD, FACC, MSCAI
    Medical Director, The Carl and Edyth Lindner Center for Research and Education
    The Christ Hospital Health Network

    3:30 – 4:30 p.m.

    4006. Stroke Risk Reduction and Left Atrial Appendage Closure: Current and Future Directions
    Industry-Expert Theater 1, #2251
    Sponsored by Boston Scientific


    • Current evidence on the safety and effectiveness of LAAC
    • Decisions in the real world: for whom do I recommend LAAC?
    • An update on pharmacological treatment for stroke in AF

    C. Michael Gibson, MD, FACC

    Christopher Granger, MD, FACC

    4014. Advancing the Treatment of Uncontrolled Hypertension with Ultrasound RDN
    Industry-Expert Theater 2, #1951
    Sponsored by ReCor Medical

    Join us to learn about the recent clinical advancements with the Ultrasound Renal Denervation (uRDN) system, the device-based treatment option for patients struggling to control hypertension, including the results of RADIANCE-HTN SOLO and TRIO studies (blinded, sham-controlled, powered to demonstrate blood pressure lowering effectiveness at 2 months). In addition, hear the experts' perspectives on the ideal patients and how to establish interventional hypertension therapy.

    Michael A. Weber, MD, FACP, FACC, FAHA (Moderator)
    Professor of Medicine Division of Cardiovascular Medicine
    State University of New York, Downstate Medical Center
    Editor-in-Chief Emeritus, The Journal of Clinical Hypertension

    Ajay J. Kirtane, MD, SM (Co-moderator)
    Professor of Medicine at the Columbia University Medical Center, Chief Academic Officer at Columbia Interventional Cardiovascular Care and Director at NYP/Columbia Cardiac Catheterization Laboratories

    Felix Mahfoud, MD, MA, FESC
    Professor and Senior Physician of Internal Medicine and Cardiology at Saarland University Hospital

    Michael J. Bloch, MD, FAHA, FASH, FNLA, FSVM, FACP
    Associate Professor, Department of Internal Medicine, University of Nevada School of Medicine
    Medical Director, Vascular Care, Heart and Vascular Health, Reno, NV

    Monday, April 4

    9:45 – 10:45 a.m.

    4007. SCD Risk and Sleep Apnea: Managing Outcomes in the Heart Failure Patient
    Industry-Expert Theater 1, #2251
    Sponsored by ZOLL

    In this program, the faculty will discuss the management of Heart Failure patients and their comorbidities, including Sudden Cardiac Death (SCD) risk and sleep disordered breathing.

    The expert speakers will focus on providing healthcare professionals with clinically actionable information on risk stratification and Sleep Apnea to manage cardiac outcomes. A moderated panel discussion with Q&A session follows the presentations.

    Virend K. Somers, MD, PhD (moderator)
    Professor of Medicine
    Department of Cardiovascular Medicine
    Mayo Clinic, Rochester, MN

    Sandra A. Carey, PhD, ANP-BC, FHFSA
    CVD-Sleep Scientist/Program Developer
    Center for Advanced Heart & Lung Disease
    Baylor Scott & White, Dallas, TX

    Marat Fudim, MD, MHS
    Assistant Professor
    Cardiology, Advanced Heart Failure, Transplant
    Duke University
    Duke Clinical Research Institute, Durham, NC

    4015. Understanding HCM and the Diagnostic Challenge
    Industry-Expert Theater 2, #1951
    Sponsored by Bristol Myers Squibb

    Hypertrophic cardiomyopathy (HCM) is a chronic, progressive myocardial disease estimated to be present in roughly 700,000 people in the United States, and, of that number, many patients are estimated to be undiagnosed. This signifies a large gap in the awareness and understanding of HCM.

    This session will address common misconceptions to help raise awareness and provide approaches to help overcome barriers to differential diagnosis in appropriate patients.

    Srihari S. (Hari) Naidu, MD, FACC, FAHA, FSCAI
    Professor of Medicine
    New York Medical College
    Valhalla, New York

    12:15 – 1:15 p.m.

    4008. Realizing the Future of HDL: Uncovering Potential Cardioprotective Benefits of Cholesterol Efflux
    Industry-Expert Theater 1, #2251
    Sponsored by CSL Behring

    Can we harness the cardioprotective power of cholesterol efflux to improve outcomes for patients at high risk of recurrent cardiovascular events? Join C. Michael Gibson, MS, MD (Chair), Martha Gulati, MD, MS, FACC, and Kenneth W. Mahaffey, MD, as they discuss patients' residual risk in the 90-day period following an acute myocardial infarction despite receiving current standard of care, and explore how our understanding of atherosclerotic cardiovascular disease is changing. The session will begin with a short presentation by Dr. Gibson, followed by a rich, engaging dialogue between the faculty members.

    C. Michael Gibson, MS, MD
    Interventional Cardiologist, Beth Israel Lahey Health, Cambridge, MA, USA
    CEO of Baim Institute for Clinical Research (formerly known as Harvard Clinical Research Institute) and PERFUSE
    Professor of Medicine, Harvard Medical School, Boston, MA, USA

    Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC
    Cardiologist & Professor of Medicine
    University of Calgary, Calgary, Alberta, Canada
    President-elect, American Society for Preventive Cardiology

    Kenneth W. Mahaffey, MD
    Professor of Cardiovascular Medicine
    Associate Dean, Clinical Research, School of Medicine
    Vice Chair, Clinical Research, Department of Medicine
    Director, Stanford Center for Clinical Research
    University of Stanford, Stanford, CA, USA

    4016. Navigating Uncharted Waters: How Do We Improve Care in HFpEF+AF?
    Industry-Expert Theater 2, #1951
    Sponsored by Sanofi

    Leading causes of stroke and mortality and independently associated with poor patient-reported outcomes, heart failure (HF) and atrial fibrillation (AF) have reached near epidemic proportions in our society. While each condition alone represents a significant health burden, patients with both conditions experience a deteriorating spiral of disease progression that leads to poorer prognosis and worse patient-reported outcomes than patients with either condition alone. Although timely treatment, including early rhythm control for AF patients with HF, can improve clinical outcomes, siloed care leaves many patients undiagnosed and undertreated. Join our expert panel as they discuss the challenges in caring for these patients, review the latest data in patient management, and evaluate strategies to help bridge the clinical divide and improve patient care.

    Javed Butler, MD, MPH, MBAPresident, Baylor Scott and White Research Institute, Dallas, Texas
    Distinguished Professor of Medicine, University of Mississippi, Jackson, Mississippi

    Andrea M. Russo, MD, FACC, FHRS, FAHA
    Professor of Medicine, Cooper Medical School of Rowan University, Academic Chief, Division of Cardiology
    Director, Cardiac Electrophysiology and Arrhythmia Services
    Director, CCEP Fellowship Cooper University Hospital, Camden, New Jersey

    Information current as of March 16, 2022

    Industry-Expert Theater presentations are not part of ACC.22, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

    American College of Cardiology

    © 2022 American College of Cardiology Foundation. Visit

    Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us